Digital
3rd-4th December 2020

2nd Edition MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases (Time zone- Greenwich Mean Time (GMT)

New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.

MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases scheduled to be held on 3rd -4th December 2020 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally renowned speakers can describe how their analysis journeys have developed the response towards up to date challenges. The attending specialists and trade partners will offer an incredible networking expertise.
 

This conference will gather scientists, researchers, entrepreneurs, academicians, medical officers, CEO’s, CSO’s and technologists from everywhere around the globe to discuss on the newest scientific advances within the field of rare diseases & orphan drugs that facilitate to form current and future challenges in drug analysis.

WHAT TO EXPECT

Key Highlights

  • The growth of orphan drugs for rare diseases
  • Challenges and opportunities in treatment
  • Improving clinical trials for rare diseases
  • Classification by types of rare diseases and therapy options
  • Commercialization and pricing strategies for orphan drugs
  • Discussion on current regulatory measures for manufacturing orphan drugs

Why Attend?

  • 100+ experts attending
  • Participate in constructive discussion with leading industry experts and decision-makers from pharmaceutical manufacturers who will tackle the most important issues in Rare disease diagnosis.
  • Best opportunity to showcase your work and research in front of industry leaders.
  • Develop your skills by learning new competencies and acquire knowledge from pioneers all around the world.

CONFERENCE AGENDA
Enquire Now

Sponsor/Exhibit Delegate
CONFERENCE SPEAKERS
Speakers
Monica Vinhas de Souza, MD, PhD
Monica Vinhas de Souza, MD, PhD
Executive Member of the research and ethics committee, Hospital de Clínicas de Porto Alegre (HCPA)
Stephen Groft
Stephen Groft
Senior Advisor to the Director NCATS, , NIH
Sebastian Waldmeier
Sebastian Waldmeier
Brand Director Gene Therapy/Luxturna, Region Europe, Novartis
Kimon Doukoumetzidis
Kimon Doukoumetzidis
Region Europe Brand Director Gene Therapy – Luxturn, Novartis
 Dairine Dempsey
Dairine Dempsey
Non-Executive Director/Consultant, OmniSpirant Limited | Soleno Therapeutics, Inc.
Alex Monaghan
Alex Monaghan
Senior Director, Business Partnerships , Within3
Rudiger Schulze
Rudiger Schulze
Vice President and General Manager, Germany and Central / Eastern Europe , Ultragenyx Pharmaceutical Inc.
 David Garzon Lafuente
David Garzon Lafuente
Head Iberia Rare Diseases, Chiesi
Please contact [email protected] for speaking opportunity
SPONSORS
Gold
example-image

Volv

Silver
example-image

Within3

Visiting Partners
example-image

Angelini

Speaking Partner
example-image

Mendelian

PAST EVENT GALLERY